BioCentury
ARTICLE | Clinical News

Fate to bring iPS cell therapy to clinic

December 7, 2018 12:59 AM UTC

Fate Therapeutics Inc. (NASDAQ:FATE) gained $1.26 to $15.36 on Nov. 30 after announcing that FDA will allow the biotech to move forward with a clinical trial of its allogeneic NK cell therapy FT500, which Fate says would be the first U.S. trial of an iPS cell-derived therapy.

The move put Fate just shy of a $1 billion market cap...

BCIQ Company Profiles

Fate Therapeutics Inc.